VYNE Therapeutics Inc. (VYNE)
Develops topical and oral anti-inflammatory drugs for chronic skin and immune conditions.
$28.56+0.00%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago+61.8%
The outlook
VYNE trades near the lower end of its 52-week range, sitting about a quarter of the way up from its recent lows. The stock shows a mixed technical picture relative to its moving averages, with neutral analyst sentiment reflected in a middling StockGlow score. Current price momentum appears flat.
What’s behind the score
Price trendMixed vs its moving averages
52-week range24% of the way from its 52-week low to high
Market cap
$19.1M
52-wk high
$74.45
52-wk low
$14.05
50-day avg
$34.08
200-day avg
$28.15
Trailing P/E
—